The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
Pedro J. Romero, MD, JITC Editor-in-Chief, welcomes applications from interested individuals who would like to take advantage of the many benefits of serving as a JITC manuscript reviewer. Benefits include:
JITC launched two new sections in 2020 and is now collecting submissions for peer review. Read more about these sections, "Immune Cell Therapies and Immune Cell Engineering" and "Oncolytic and Local Immunotherapy," and submit today!
The Journal for ImmunoTherapy of Cancer (JITC) increased its impact factor to 13.751 on June 30, 2021. JITC’s Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 5% percent of all journals published in the category of immunology and top 7% in the category of oncology.Published in the annual Journal Citation Reports (JCR), the latest JITC impact factor is a calculation determined on the number of 2020 citations accumulated for JITC manuscripts published in 2018 and 2019. Other valuable journal metrics for JITC may be found on the journal website.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on processing fees for all JITC articles submitted and accepted in 2021.
For questions regarding the discount that would be verified and applied upon post-review acceptance, please contact JITCEditor@sitcancer.org or (414) 271-2456.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Increasing infiltration of CD8+ T cells within tumor tissue predicts a better prognosis and is essential for response to checkpoint blocking therapy. Furthermore, current clinical protocols use unfractioned T cell populations as the starting point for transduction of chimeric antigen receptors (CARs)-modified T cells, but the optimal T cell subtype of CAR-modified T cells remains unclear. Thus, accurately identifying a group of cytotoxic T lymphocytes with high antitumor efficacy is imperative. Inspired by the theory of yin and yang, we explored a subset of CD8+ T cell in cancer with the same phenotypic characteristics as highly activated inflammatory T cells in autoimmune diseases.
Several therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to make informed treatment decisions. Herein we characterize adjuvant nivolumab select (immune-related) treatment-related adverse events (TRAEs) and evaluate possible associations between safety and recurrence-free survival (RFS) in the phase III CheckMate 238 trial.
I would like to participate as well ------------------------------ Enrique Arenas Lahuerta PhD Postdoctoral Fellow Vall D'Hebron Institute of Oncology ------------------------------
Hi Priya, I know that you posted this a while back, just wondering if you still needed any more writers? Thanks, Insiya ------------------------------ Insiya Jafferji PhD Sr. Research Scientist The Univeristy of Texas MD Anderson Cancer Center Houston ...
Surgical Oncology/Cancer Immunotherapy Research Fellowships are available at the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under the leadership of Dr. Steven A. Rosenberg.
These fellowships are open to US categorical ...
Hi Todd, We would love to have your chapter but the deadline for book chapters has passed. However, if you can get your contribution by October 25, 2021, we should be able to review it for inclusion. Please let me know. Priya Hays
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org